



PATENT CASE IN01156

1/17/02
TECH CENTER 1000/2300
RECEIVED
JAN 15 2001

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

A. Arasappan et al.

Serial No.: 09/909,077

Filed: July 19, 2001



) Examiner: Not assigned yet
) Group Art Unit: Not assigned yet
) Atty. Docket No.: IN01156

For: NOVEL PEPTIDES AS NS3-SERINE PROTEASE INHIBITORS OF HEPATITIS C VIRUS

Assistant Commissioner for Patents
Washington, D.C. 20231

RECEIVED

JAN 11 2002

INFORMATION DISCLOSURE STATEMENT

GROUP 3600

Sir:
It is requested that the following documents cited in the application, as listed below and in the accompanying form PTO-1449, be considered and made of record.Documents cited in the Application:

U.S. 5,712,145
WO 89/04669
WO 98/17679
WO 98/22496
WO 99/07734
WO 00/09558
WO 00/09543
EP 381 216

Publications:

Pizzi et al. (1994) Proc. Natl. Acad. Sci (USA) 91:888-892
Failla et al. (1996) Folding & Design 1:35-42
Kollykhalov et al. (1994) J. Virol. 68:7525-7533
Komoda et al. (1994) J. Virol. 68:7351-7357
Landro et al. (1997) Biochem. 36:9340-9348
Ingallinella et al. (1998) Biochem. 37:8906-8914
Llinás-Brunet et al. (1998) Bioorg. Med. Chem. Lett. 8:1713-1718
Martin et al. (1998) Biochem. 37:11459-11468
Dimasi et al. (1997) J. Virol. 71:7461-7469
Martin et al. (1997) Protein Eng. 10:607-614
Elzouki et al. (1997) J. Hepat. 27:42-48
BioWorld Today 9(217): 4 (November 10, 1998)
Berenguer et al. (1998) Proc. Assoc. Am. Physicians 110(2):98-112
Hoofnagle et al. (1997) N. Engl. J. Med. 336:347
R. Zhang et al., Analytical Biochemistry, 270 (1999) 268-275

BEST AVAILABLE COPY



D. L. Sali *et al*, *Biochemistry*, 37 (1998) 3392-3401
K. Barlos *et al*, *Int. J. Pept. Protein Res.*, 37 (1991), 513-520
K. Holmberg *et al*, *Acta Chem. Scand.*, B33 (1979) 410-412
A. Marchetti *et al*, *Synlett.*, S1 (1999) 1000-1002
W. Han *et al*, *Bioorganic & Biomedicinal Chem Lett.*, 10 (2000) 711-713
S. Agrawal *et al*, "Development and Characterization of Hepatitis C Virus Serine Protease Cell-based Trans-Cleavage Assay", *Hepatology* Supplement to Volume 30 (No. 4, Part 2, October 1999), Abstract No. 615 (Proceedings of AASLD 50th Annual Meeting, Dallas, Texas, November 5-9, 1999.
L. Hughes, *Org. Reactions*, 42 (1992) 335.
R. F. Heck, *Org. Reactions*, 27 (1989) 345-390.

The submission of these documents is not to be presumed as an admission that these documents are prior art. The documents are being furnished solely for their possible utility in the examination of the present case. Since no Office Action has issued on the merits of this case, Applicants believe that no fee is due at this time. If, however, any fees are due, the Office may charge such fees to Deposit Account No. 19-0365.

If the Examiner has any questions, the Examiner is invited to contact the undersigned.

December 19, 2001
Schering-Plough Corporation
2000 Galloping Hill Road
Patent Department, K-6-1,1990
Kenilworth, NJ 07033
Tel: (908) 298-5068
Fax: (908) 298-5388

Respectfully submitted,

Palaiyur S. Kalyanaraman
Attorney for Applicants
Reg. No. 34,634

I hereby certify that this correspondence
is being deposited with the U.S. Postal
Service as First Class Mail in an envelope
addressed to Assistant Commissioner for
Patents, Washington, D.C. 20231 on


December 19, 2001

Palaiyur S. Kalyanaraman
Registered Representative

Signature and Date of Signature

RECEIVED
JAN 15 2001
TECH CENTER 1600/2600

BEST AVAILABLE COPY



Sheet 1 of 1

TECH CENTER 1600/2000
JAN 5 2001RECEIVED
U.S. PATENT AND TRADEMARK OFFICE

BEST AVAILABLE COPY

FORM PTO-1449

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICEINFORMATION DISCLOSURE STATEMENT
BY APPLICANT

(Use several sheets if necessary)

ATTY. DOCKET NO.:
IN01156SERIAL NO.:
09/909,077APPLICANT:
SAKSENA, et alFILING DATE:
July 19, 2001GROUP:
To Be Assigned

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE IF APPROPRIATE
AA	U.S. 5,712,145					
AB						

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
AC	WO 89/04669					
AD	WO 98/17679					
AE	WO 98/22496					
AF	WO 98/07734					
AG	WO 00/09558					
AH	WO 00/09543					
AI	EP 381 216					
AJ						
AK						

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

AL	Pizzi, (1994) <i>Proc. Natl. Acad. Sci.(USA)</i> 91:888-892
AM	Failla (1996) <i>folding & Design</i> 1:35-42
AN	Kollykhalov (1994) <i>J. Virol.</i> 68:7525-7533
AO	Komoda (1994) <i>J. Virol.</i> 68:7351-7357
AP	Landro (1997) <i>Biochem</i> 36:9340-9348
AQ	Ingallinella (1998) <i>Biochem</i> 37:8906-8914
AR	Llinas-Brunet (1998) <i>Bioorg. Med. Chem. Lett.</i> 8:1713-1718
AS	Martin (1998) <i>Biochem</i> 37:11459-11468
AT	Dimasi (1997) <i>J. Virol.</i> 71:7461-7469
AU	Martin (1997) <i>Protein Eng.</i> 10:607-614
AV	Elzouki (1997) <i>J. Hepat.</i> 27:42-48
AW	<i>Bio World Today</i> 9(217): 4 (November 10, 1998)
AX	Berenguer (1998) <i>Proc. Assoc. Am. Physicians</i> 110(2): 98-112
AY	Hoeffnagle (1997) <i>New England Journal Med.</i> 336:347
AZ	Zhang (1999) <i>Analytical Biochemistry</i> 270:268-275
BA	Sali (1998) <i>Biochemistry</i> 3392-3401
BB	Barlos (1991) <i>Int. J. Pept. Protein Res</i> 513-520
BC	Holmberg (1979) <i>Acta Chem. Scand.</i> , B33:410-412
BD	Agrawal(1999) <i>Hepatology Supplement to Vol 30 "Development and Characterization of Hepatitis C Virus Serine Protease Cell-based Trans-Cleavage Assay"</i>
BE	Hughes (1992) <i>Org. Reactions</i> 42:335
BF	Heck (1989) <i>Org. Reactions</i> 27:345-390
BG	Han, (2000) <i>Bioorganic & Medicinal Chemistry Letters</i> 10 "α-Ketoamides, α-Ketoesters and α-Ketones as HCV NS3 Protease Inhibitors" pp. 711-713.
BH	Marchetti(1999) <i>Synlett</i> , Vol. S1, "Synthesis of Two Novel Cyclic Biphenyl Ether Analogs of an Inhibitor of HCV NS3 Protease", pp 1000-1002.

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.